My title
» Lung Cancer

Lung Cancer

LUNG CANCER CLINICAL TRIALS

Study Link Study Status Study Title Principal Investigator
ALCHEMIST Active-Enrolling Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) PI: Graze
ATLANTIS Active-Enrolling Clinical Trial of Lurbinectedin (PM01183) Plus Doxorubicin (DOX) Versus Topotecan in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line PI: Graze
 

 A081105

Active-Enrolling RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF ERLOTINIB OR PLACEBO IN PATIENTS WITH COMPLETELY RESECTED EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTANT NON-SMALL CELL LUNG CANCER (NSCLC) PI: Graze
CALGB 140503 Active-Enrolling A PHASE III RANDOMIZED TRIAL OF LOBECTOMY VERSUS SUBLOBAR RESECTION FOR SMALL (≤ 2 CM) PERIPHERAL NON-SMALL CELL LUNG CANCER PI: Cattaneo
Checkmate 370 Active-Enrolling Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after induction chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies PI: Graze
DENALI Active-Enrolling  

A 3-Arm Phase 2 Double-Blind Randomized Study of Carboplatin, Pemetrexed Plus Placebo versus Carboplatin, Pemetrexed plus 1 or 2 Truncated Courses of Demcizumab in Subjects with Non-Squamous Non-Small Cell Lung Cancer
PI: Graze
E4512 Active-Enrolling A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein PI: Graze
EA5142 Active-Enrolling Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) – A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-small Cell Lung Cancers PI: Graze
STABLE-MATES Active-Enrolling Joint Lung Cancer Trialist’s Coalition (JoLT – Ca) A Randomized Phase III Study of Sublobar Resection (SR) versus Stereotactic Ablative Radiotherapy (SAbR) in High Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC) PI: Young

 

 

 

Our Studies